Willie Underwood, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,825 of the $10,665 with a category attached, or 73.4%. Pfizer accounts for 93.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $5,525 and has fallen 95.6% since, to $245 in 2025.
Across 17 payments — averaging $627.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- Progenics Pharmaceuticals, Inc.$307
- Coloplast$146
- Astellas Pharma US Inc$99
- Boston Scientific$99
- Tolmar Pharmaceuticals, Inc.$25
- plus $13 from 1 others
What the payments were for
- Speaking & faculty fees$7,82573%
- Travel & lodging$2,11220%
- Food & beverage$7147%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $9,976 |
| Progenics Pharmaceuticals, Inc. | 3 | $307 |
| Coloplast | 2 | $146 |
| Astellas Pharma US Inc | 1 | $99 |
| Boston Scientific | 1 | $99 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$209
How this compares
$10,665 in reported general payments places this provider in the 85th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 40 | $410 |
| Finasteride | 24 | $285 |
| Oxybutynin Chloride | 16 | $261 |
Paid to pharmacies, not to this prescriber.
Other urology in Bend
- Matt AshleyBend$212K
- Jason FlamiatosBend$11K
- Andrew NeebBend$9K
- Hagop SarkissianBend$4K
- Michael LavelleBend$3K
- Daniel WillisBend$3K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.